Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response

BACKGROUND: Although immune checkpoint inhibitor (ICI) is regarded as a breakthrough in cancer therapy, only a limited fraction of patients benefit from it. Cancer stemness can be the potential culprit in ICI resistance, but direct clinical evidence is lacking. METHODS: Publicly available scRNA-Seq...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhen, Wang, Zi-Xian, Chen, Yan-Xing, Wu, Hao-Xiang, Yin, Ling, Zhao, Qi, Luo, Hui-Yan, Zeng, Zhao-Lei, Qiu, Miao-Zhen, Xu, Rui-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052621/
https://www.ncbi.nlm.nih.gov/pubmed/35488273
http://dx.doi.org/10.1186/s13073-022-01050-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052621/
https://www.ncbi.nlm.nih.gov/pubmed/35488273
http://dx.doi.org/10.1186/s13073-022-01050-w

Ejemplares similares